Trial Profile
Pharmacokinetics of atazanavir at the dose of 300mg or 400mg in subjects with HIV-1 infection and non-decompensated hepatic cirrhosis (Child-Pugh A o B, Metavir F4), crossover study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2012
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms EPAZANAVIR-1
- 25 Aug 2011 New trial record